Hong Kong Luxury Stock News

SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?

Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026. The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the...
SEHK:6990
SEHK:6990Biotechs

A Look At Sichuan Kelun Biotech (SEHK:6990) Valuation After SKB103 IND Approval And Pipeline Progress

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just received Chinese regulator approval for its SKB103 IND in advanced solid tumors, marking a new clinical milestone that comes alongside recent earnings and oncology trial updates. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The regulatory green light for SKB103 comes after a series of oncology updates and full-year 2025 results. The share price has reacted, with a 7.07% 1-day share price return and 18.12% 30-day...
SEHK:1128
SEHK:1128Hospitality

Wynn Macau (SEHK:1128) Valuation Check After 2025 Results And Higher Final Dividend

Wynn Macau (SEHK:1128) has drawn fresh attention after releasing full year 2025 results that show revenue broadly steady while net income declined, alongside a higher recommended final ordinary dividend. See our latest analysis for Wynn Macau. The full year results and higher proposed dividend come after a mixed share price run, with a 7 day share price return of 4.50%, a 90 day share price return of 6.86% and a year to date share price return of 7.17%, while the 1 year total shareholder...
SEHK:6922
SEHK:6922Medical Equipment

Cryofocus Medtech (SEHK:6922) Loss Narrowing Challenges Bearish Narratives In FY 2025 First Half

Cryofocus Medtech (Shanghai) (SEHK:6922) has just posted its FY 2025 first half results, with revenue of ¥51.1 million and a basic EPS loss of ¥0.10, while trailing 12 month figures show revenue of ¥95.3 million and a basic EPS loss of ¥0.16. The company has seen revenue move from ¥19.5 million in the first half of FY 2024 to ¥34.1 million in the second half and then to ¥51.1 million in the first half of FY 2025, alongside net income losses of ¥52.2 million, ¥52.2 million and ¥23.8 million...
SEHK:6959
SEHK:6959Commercial Services

Changjiu Holdings (SEHK:6959) Margin Drop From 23.7% To 8.7% Challenges Bullish Narratives

Changjiu Holdings (SEHK:6959) has just released its FY 2025 numbers, with first half revenue of C¥696.7 million and basic EPS of C¥0.33. This sets the stage against a trailing 12 month line that shows C¥1.62 billion in revenue and EPS of C¥0.70. Over recent reporting periods, revenue has moved from C¥337.2 million and EPS of C¥0.29 in 1H FY 2024, to C¥340.4 million and EPS of C¥0.51 in 2H FY 2024, before reaching the latest 1H FY 2025 levels. This leaves investors to weigh this earnings...
SEHK:9889
SEHK:9889Banks

Dongguan Rural Commercial Bank (SEHK:9889) Margin Compression Reinforces Bearish Narratives In FY 2025 Results

Dongguan Rural Commercial Bank (SEHK:9889) has wrapped up FY 2025 with fourth quarter revenue of C¥1.4b and net income of C¥209.3m, alongside trailing twelve month EPS of C¥0.56 on revenue of C¥8.3b. Over recent periods, revenue has ranged from C¥2.5b in the first quarter of 2025 to C¥1.4b in the fourth quarter, with quarterly net income moving between C¥1.6b and C¥209.3m, and trailing net profit margin easing from 52.4% to 46.4% over the last year. This puts the focus squarely on how...
SEHK:2418
SEHK:2418Transportation

Deewin Tianxia (SEHK:2418) Margin Rebound In 1H 2025 Challenges Bearish Profitability Narratives

Deewin Tianxia (SEHK:2418) has released its FY 2025 figures, reporting first half revenue of about CN¥1.1b and basic EPS of CN¥0.04. This is set against a trailing 12‑month picture where EPS is CN¥0.03 on revenue of roughly CN¥2.8b and net income of CN¥68.3m. Over recent periods the company’s revenue has moved from about CN¥1.3b in 1H 2024 to CN¥1.3b in 2H 2024, and then to roughly CN¥1.1b in 1H 2025. Basic EPS shifted from CN¥0.05 in 1H 2024 to CN¥0.02 in 2H 2024, and then to CN¥0.04 in 1H...
SEHK:317
SEHK:317Machinery

CSSC Offshore And Marine Engineering SEHK 317 Margin Jump Reinforces Turnaround Narrative

CSSC Offshore & Marine Engineering (Group) (SEHK:317) just closed FY 2025 with fourth quarter revenue of C¥6.2b and basic EPS of C¥0.25, alongside trailing twelve month EPS of C¥0.71 on revenue of C¥20.5b. This was capped by earnings growth of 167.3% over the last year. Over recent periods the company has seen quarterly revenue range from C¥3.6b to C¥6.7b with EPS moving between C¥0.03 and C¥0.25, while trailing twelve month net income reached C¥1.0b as margins improved from 1.9% to 4.9%...
SEHK:2333
SEHK:2333Auto

Great Wall Motor (SEHK:2333) Margin Compression Challenges Bullish Growth Narratives In FY 2025

Great Wall Motor (SEHK:2333) has wrapped up FY 2025 with fourth quarter revenue of CN¥69.2b and basic EPS of CN¥0.15, while trailing twelve month figures show revenue of CN¥222.8b and EPS of CN¥1.16. Over recent quarters the company has seen revenue move from CN¥59.9b in Q4 2024 to CN¥69.2b in Q4 2025, with quarterly EPS shifting from CN¥0.27 to CN¥0.15. This sets up an earnings picture where a 4.4% trailing net margin and a CN¥4.1b one off gain leave investors weighing how durable the...
SEHK:1763
SEHK:1763Medical Equipment

China Isotope & Radiation (SEHK:1763) Margin Compression Reinforces Bearish Narratives On Earnings Resilience

China Isotope & Radiation (SEHK:1763) has opened FY 2025 with first half revenue of C¥2,857.8 million and basic EPS of C¥0.54, setting the tone for how the year is shaping up after a strong back half of FY 2024. The company has seen revenue move from C¥2,810.3 million in 1H 2024 to C¥4,764.5 million in 2H 2024, with basic EPS rising from C¥0.48 to C¥0.79 over the same periods, and trailing twelve month EPS most recently coming in at C¥1.02. For investors, the key question now is how these...
SEHK:1570
SEHK:1570Real Estate

Weiye Holdings (SEHK:1570) Revenue Collapse Reinforces Bearish Narratives Despite Smaller Recent Loss

Weiye Holdings (SEHK:1570) has released its FY 2025 figures with first half revenue of C¥11.4 million and a basic EPS loss of C¥0.11, while trailing twelve month revenue came in at C¥59.1 million with a basic EPS loss of C¥2.31. Over recent periods the company has seen first half revenue move from C¥1,352.0 million in 2023 to C¥32.0 million in 2024 and C¥11.4 million in 2025, alongside first half basic EPS losses of C¥0.21, C¥0.35 and C¥0.11 respectively. With the share price at C¥7.20, this...
SEHK:991
SEHK:991Renewable Energy

Datang Power (SEHK:991) Margin Improvement To 6.1% Challenges Cautious Narratives On Profitability

Datang International Power Generation (SEHK:991) has reported its FY 2025 results with fourth quarter revenue of C¥31.9b and basic EPS of C¥0.0256, while trailing twelve month EPS stands at C¥0.3155 on revenue of C¥121.3b. Over the past year, trailing net income excluding extra items increased from C¥4,506.2m to C¥7,386.3m, and trailing net profit margin moved from 3.6% to 6.1%, pointing to more earnings being retained from each unit of sales. For investors, that shift in profitability is a...
SEHK:1401
SEHK:1401Tech

Future Machine (SEHK:1401) Margin Improvement Tests Bullish Earnings Narratives

Future Machine (SEHK:1401) has just posted its FY 2025 first half results, with revenue of C¥1.6b and net income of C¥11.2m translating to basic EPS of C¥0.011. This is set against a trailing twelve month picture of C¥4.35b in revenue, C¥41.4m in net income and C¥0.0318 in EPS. Over recent periods the company has reported revenue of C¥1.26b in 1H 2024, C¥1.66b in 2H 2024, and then C¥1.6b in 1H 2025, while basic EPS has ranged from C¥0.0099 to C¥0.0065 to C¥0.011. These headline shifts sit...
SEHK:2477
SEHK:2477IT

WellCell Holdings (SEHK:2477) Margin Compression Reinforces Bearish Earnings Narrative

WellCell Holdings (SEHK:2477) opened FY 2025 with first half revenue of CN¥90.1 million and net income of CN¥7.7 million, translating to basic EPS of CN¥0.007717 as investors weigh these figures against a current share price of HK$19.60. Over recent periods the company has seen revenue move from CN¥106.1 million in 1H 2024 to CN¥172.1 million in 2H 2024 before landing at CN¥90.1 million in 1H 2025, while basic EPS shifted from CN¥0.010885 to CN¥0.009418 and then to CN¥0.007717. These trends...
SEHK:2002
SEHK:2002Packaging

China Sunshine Paper Holdings (SEHK:2002) Margin Compression Reinforces Cautious Community Narratives

China Sunshine Paper Holdings (SEHK:2002) has reported its FY 2025 first half results with revenue of C¥3.6b and basic EPS of C¥0.08, setting a cautious tone after a period where margins have come under pressure. Over the past three reported halves, revenue has moved from C¥4.0b in 1H 2024 to C¥4.1b in 2H 2024 and then to C¥3.6b in 1H 2025. Over the same timeframe, basic EPS shifted from C¥0.18 to C¥0.08, alongside a trailing 12 month net profit margin of 2.1% versus 3.5% the prior year. For...
SEHK:3382
SEHK:3382Infrastructure

Tianjin Port Development Holdings (SEHK:3382) Margin Improvement Tests Bearish Earnings Narrative

Tianjin Port Development Holdings (SEHK:3382) has posted FY 2025 first half revenue of HK$6.9b and basic EPS of HK$0.056, with net income excluding extra items at HK$345.8m, setting the tone for its latest results. Over recent periods, revenue has moved from HK$6.7b in 1H 2024 to HK$7.0b in 2H 2024 and HK$6.9b in 1H 2025, while basic EPS has shifted from HK$0.0679 to HK$0.0442 and then HK$0.056, as profitability and margins have been recalibrated. See our full analysis for Tianjin Port...
SEHK:357
SEHK:357Infrastructure

Hainan Meilan International Airport SEHK 357 Narrowing Losses Strengthen Bullish Recovery Narrative

Hainan Meilan International Airport (SEHK:357) has reported its FY 2025 first half with revenue of C¥1,079.3 million and a basic EPS loss of C¥0.15 per share, while the trailing twelve months show revenue of C¥2.0 billion and a basic EPS loss of C¥0.59. Over recent periods, revenue has moved between C¥1,149.3 million and C¥1,021.7 million on a half year basis as basic EPS losses ranged from C¥0.52 to C¥0.28 per share, giving investors a clear view of how throughput is holding up against...
SEHK:1733
SEHK:1733Trade Distributors

E‑Commodities Holdings (SEHK:1733) Margin Compression To 1.3% Reinforces Bearish Narratives

E-Commodities Holdings (SEHK:1733) FY 2025 earnings snapshot E-Commodities Holdings (SEHK:1733) has reported FY 2025 first half revenue of HK$12.7b with basic EPS of HK$0.051, alongside trailing twelve month revenue of HK$25.2b and basic EPS of HK$0.12. This sets a clear picture of results against its current share price of HK$0.84. The company has seen revenue move from HK$19.9b and EPS of HK$0.294 in the first half of 2024 to HK$12.7b and EPS of HK$0.051 in the first half of 2025. Trailing...
SEHK:1931
SEHK:1931Healthcare

ETHK Labs (SEHK:1931) Margin Compression Reinforces Bearish Community Narratives

ETHK Labs (SEHK:1931) has opened FY 2025 with first half revenue of C¥1.27b and basic EPS of C¥0.024, putting fresh numbers behind a share price sitting at C¥1.11. The company has seen revenue move from C¥1.35b in 1H 2024 to C¥1.81b in 2H 2024 and then to C¥1.27b in 1H 2025, while basic EPS went from C¥0.093 to C¥0.082 and now C¥0.024. This sets up a results season where investors will be weighing how the recent pressure on margins fits into their expectations for the business. See our full...
SEHK:809
SEHK:809Food

Global Bio-chem Technology Group (SEHK:809) Margin Collapse Challenges Bullish Growth Narrative

Global Bio-chem Technology Group (SEHK:809) has reported FY 2025 first half revenue of HK$1.2b and a basic EPS loss of HK$0.017, setting a mixed tone after a stronger second half in FY 2024. Over the last three reported halves, revenue has moved from HK$898.5m in FY 2024 H1 to HK$1.1b in FY 2024 H2 and HK$1.2b in FY 2025 H1. EPS has swung from a loss of HK$0.018 in FY 2024 H1 to a profit of HK$0.104 in FY 2024 H2 before slipping back into a small loss in the latest period, leaving investors...
SEHK:3898
SEHK:3898Machinery

Zhuzhou CRRC Times Electric (SEHK:3898) Margin Slip Tests Bullish Rail Plus New Energy Narrative

Zhuzhou CRRC Times Electric (SEHK:3898) has reported full year 2025 results with fourth quarter revenue of about C¥9.9b and basic EPS of C¥1.01, while trailing twelve month revenue stands at roughly C¥28.7b and EPS at C¥2.99. Over recent periods, quarterly revenue has moved from around C¥6.0b in the third quarter of 2024 to C¥8.7b in the fourth quarter of 2024 and then to C¥9.9b in the fourth quarter of 2025. Basic EPS has stepped from C¥0.69 to C¥0.85 to C¥1.01 across those same quarters...